Screener
Avalo Therapeutics AVTX Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Current liabilities: | ||
| Accounts payable | $3,347 | $137 |
| Accrued expenses and other current liabilities | 17,783 | 12,803 |
| Total current liabilities | 21,130 | 12,940 |
| Royalty obligation | 2,000 | 2,000 |
| Deferred tax liability, net | 463 | 434 |
| Derivative liability, non-current | 18,530 | 18,000 |
| Other long-term liabilities | — | 35 |
Item 1. Financial Statements.
FAQ
- What is Avalo Therapeutics's total current liabilities?
- Avalo Therapeutics (AVTX) reported total current liabilities of $21.13M in Q2 2026.
- How has Avalo Therapeutics's total current liabilities changed year-over-year?
- Avalo Therapeutics's total current liabilities increased by 128.2% year-over-year, from $9.26M to $21.13M.
- What is the long-term trend for Avalo Therapeutics's total current liabilities?
- Over 5 years (2020 to 2025), Avalo Therapeutics's total current liabilities has grown at a -3.2% compound annual growth rate (CAGR), from $15.23M to $12.94M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Avalo Therapeutics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude